Showing 131 - 140 of 754,022
This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organization in Catalonia during years 2002 and 2003. We apply...
Persistent link: https://www.econbiz.de/10012708365
We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...
Persistent link: https://www.econbiz.de/10012670921
Consumers suffer from high drug prices, which stem in large part from pharmaceutical companies’ anticompetitive games. This essay discusses the crucial role antitrust enforcement agencies can play in addressing pay-for-delay settlements and product hopping and draws lessons from this...
Persistent link: https://www.econbiz.de/10013215870
How harmful can government regulations and protectionism be? We provide evidence of a sizable negative impact of government interventions on population health. In 2012, the Russian government implemented a strategy to increase the affordability of pharmaceutical drugs and develop domestic...
Persistent link: https://www.econbiz.de/10013231805
We evaluate the impact of a price cap regulation implemented in the Colombian pharmaceutical market between 2011 and 2014. To do so, we take advantage of a unique data set where we observe three sources of variation: i) differences across eighteen groups in the Anatomical Therapeutic Chemical...
Persistent link: https://www.econbiz.de/10013238087
The Prescription Drug User Fee Act (PDUFA) created rewards for the Food and Drug Administration (FDA) if it can meet goals related to the duration of the 'formal review stage' of the drug development process. Later, the Medical Device User Fee and Modernization Act (MDUFMA) set up a similar...
Persistent link: https://www.econbiz.de/10013238436
bottleneck today. Bangladesh, as an LDC abolished product patent protection in pharmaceuticals in 2008 and what the 1982 …
Persistent link: https://www.econbiz.de/10013249956
The United States spends twice as much per person on pharmaceuticals as European countries, in large part because … reference countries. We estimate a structural model of demand and supply for pharmaceuticals in the US and reference countries …
Persistent link: https://www.econbiz.de/10013210081
This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by parallel trade, i.e. trade outside the manufacturers authorized distribution channel. In particular, maximum wholesale margins, a restriction of pricing by the intermediary, and...
Persistent link: https://www.econbiz.de/10013061754
of pharmaceuticals are in this context the target of much criticism. Ensuring the safety and efficacy of pharmaceuticals … interests. Indeed, the larger regulatory landscape surrounding pharmaceuticals is undergoing significant change at this time and …
Persistent link: https://www.econbiz.de/10012752017